Taro Pharma (TARO) Posts Inline Q4 Breakeven Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Taro Provides Results for Year Ended March 31, 2015
May 26, 2015 6:44 PM EDTNet Sales Increases 14%, Operating Income and E.P.S. Up 23% and 39%, respectively
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) today provided unaudited financial results for the quarter and year ended March 31, 2015.
Quarter ended March 31, 2015 Highlights - compared to March 31, 2014
Net sales of $244.2 million, increased $57.0 million, or 30.5%, on flat volumes Gross profit, as a percentage of net sales, was 81.8%, compared to 75.5% an increase of $58.3 million or 41.2% Research and development expenses increased $10.7 million to $23.9 million... More